Once-weekly exenatide versus once- or twice-daily insulin detemir in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas

This study is the first to compare EQW and insulin detemir, with respect to glycaemic control, body weight, lipids, safety, tolerability, and patient-reported outcomes in patients with type 2 diabetes whose diabetes was inadequately controlled with metformin (with or without sulfonylureas). Patients were randomised to EQW (2 mg) or detemir (once or twice daily, titrated to achieve fasting plasma ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news